Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, while sulfonylureas signaled faster decline without it.
|Articles|September 3, 2021
Pharmacy Clinical Pearl of the Day: Hypokalemia and Hyperkalemia
Author(s)Saro Arakelians, PharmD
Kidney disease is among the most common causes of both hyperkalemia and hypokalemia.
Advertisement
Clinical Pearl of the Day: Hypokalemia and Hyperkalemia
- Hyperkalemia is high potassium levels.
- Hypokalemia is low potassium levels.
Explanation:
- Normal potassium levels in the body: 3.6- 5.2 (mmol/L).
- Most common causes of hyperkalemia include acute and chronic kidney disease, as well as medications.
- Most common causes of hypokalemia include medication use, such as water pills and kidney disease, as well as alcohol consumption.
- Hyperkalemia treatment options: Patiromer (Veltassa), sodium zirconium (Lokelma)
- Hypokalemia treatment options: Klor-Con, K-Tab, potassium chloride
Reference:
Advertisement
Related to this article
Authors of a pharmacist-directed transitions of care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
The approval is supported by data from the phase 3 FINE-ONE clinical trial.
Infection prevention during bispecific antibody treatment requires pharmacists to coordinate baseline screening, antimicrobial prophylaxis, immunoglobulin monitoring, vaccination, and rapid evaluation of suspected infections.
Linvoseltamab drives deep, MRD-negative responses in high-risk smoldering multiple myeloma, raising earlier-treatment and payer coverage questions.
Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.
An investigational glypican-3–directed CAR T-cell therapy engineered to express IL-15 and IL-21 produced a complete response lasting at least 1 year in a child with chemotherapy-resistant metastatic hepatoblastoma.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
2
Expert Q&A: Pharmacists Address Pneumococcal Vaccine Hesitancy and Screening Complexity in Transitions of Care
3
Not So Rare After All: Pharmacists Weigh In on Diagnosing and Managing ATTR-CM
4
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
5